ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Cash & Equivalents	3.14	-	0.33	0.17
Cash & Cash Equivalents	3.14	0	0.33	0.17
Cash Growth	-	-	88.12%	-
Other Current Assets	0.22	-	0.48	0.16
Total Current Assets	3.35	-	0.81	0.34
Property, Plant & Equipment	0.01	-	0.03	0.04
Other Long-Term Assets	18.75	-	0.29	0.31
Total Long-Term Assets	18.76	-	0.31	0.35
Total Assets	22.11	-	1.13	0.69
Accounts Payable	8.43	-	2	2.31
Current Debt	0.01	-	9.15	2.13
Other Current Liabilities	1.75	-	2.47	3.11
Total Current Liabilities	10.19	-	13.63	7.56
Long-Term Debt	0	-	0	1.69
Other Long-Term Liabilities	0.84	-	0	0
Total Long-Term Liabilities	0.84	-	0	1.69
Total Liabilities	11.04	-	13.63	9.24
Total Debt	0.01	-	9.15	3.82
Debt Growth	-	-	139.75%	-
Retained Earnings	-103.22	-	-52.9	-44.81
Shareholders' Equity	11.07	-	-12.83	-8.89
Net Cash / Debt	3.13	0	-8.82	-3.64
Net Cash Per Share	3.21	-	-12.78	-5.39
Working Capital	-6.84	-	-12.81	-7.22
Book Value Per Share	11.36	-	-18.58	-13.16

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).